-

Kardigan to Present at Two September Investor Conferences

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, will participate at the following conferences in September.

2026 Cantor Global Healthcare Conference
Fireside Chat: Wednesday, September 9, 2026, at 1:35 pm ET

Baird's 2026 Global Healthcare Conference
1x1 and small group meetings: Tuesday, September 15, 2026

A live webcast of the fireside chat may be accessed via the Investors & Media section of the Kardigan website at https://ir.kardigan.bio/. Following the event, a replay of the presentations will be available on the website for a limited time.

About Kardigan

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. Learn more about Kardigan and its mission at Kardigan.bio.

Contacts

Media:
Michael Bachner
Executive Director, Corporate Communications
+1 (609) 664-7308
mbachner@kardigan.bio

Investors:
Clayton Robertson
Vice President, Investor Relations
investors@kardigan.bio

Kardigan, Inc.

NASDAQ:KARD

Release Summary
Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference
Release Versions
$Cashtags
Hashtags

Contacts

Media:
Michael Bachner
Executive Director, Corporate Communications
+1 (609) 664-7308
mbachner@kardigan.bio

Investors:
Clayton Robertson
Vice President, Investor Relations
investors@kardigan.bio

Social Media Profiles
More News From Kardigan, Inc.

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates....

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan announced the closing of its initial public offering....

Kardigan Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16 per share. The gross proceeds from the offering are expected to be $400 million, before unde...
Back to Newsroom